Literature DB >> 23911592

Cerebrospinal fluid inflammatory markers in Parkinson's disease--associations with depression, fatigue, and cognitive impairment.

Daniel Lindqvist1, Sara Hall, Yulia Surova, Henrietta M Nielsen, Shorena Janelidze, Lena Brundin, Oskar Hansson.   

Abstract

Neuroinflammation may be involved in the pathophysiology of Parkinson's disease (PD) and specifically in non-motor symptoms such as depression, fatigue and cognitive impairment. The aim of this study was to measure inflammatory markers in cerebrospinal fluid (CSF) samples from PD patients and a reference group, and to investigate correlations between non-motor symptoms and inflammation. We quantified C-reactive protein (CRP), interleukin-6, tumor necrosis factor-alpha, eotaxin, interferon gamma-induced protein-10, monocyte chemotactic protein-1 (MCP-1), and macrophage inflammatory protein 1-β in CSF samples from PD patients (N=87) and the reference group (N=33). Sixteen of the PD patients had a dementia diagnosis (PDD). We assessed symptoms of fatigue, depression, anxiety and cognitive function using the Functional Assessment of Chronic Illness Therapy-Fatigue, the Hospital Anxiety and Depression Scale, and the Mini Mental State Examination, respectively. There were no significant differences in mean levels of inflammatory markers between PD patients and the reference group. After controlling for age, gender and somatic illness, patients with PDD had significantly higher levels of CRP compared to non-demented PD patients (p=0.032) and the reference group (p=0.026). Increased levels of inflammatory markers in CSF were significantly associated with more severe symptoms of depression, anxiety, fatigue, and cognition in the entire PD group. After controlling for PD duration, age, gender, somatic illness and dementia diagnosis, high CRP levels were significantly associated with more severe symptoms of depression (p=0.010) and fatigue (p=0.008), and high MCP-1 levels were significantly associated with more severe symptoms of depression (p=0.032). Our results indicate that non-motor features of PD such as depression, fatigue, and cognitive impairment are associated with higher CSF levels of inflammatory markers.
Copyright © 2013 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  C-reactive protein; Cerebrospinal fluid; Cytokines; Dementia; Depression; Fatigue; Neuroinflammation; Parkinson’s disease

Mesh:

Substances:

Year:  2013        PMID: 23911592     DOI: 10.1016/j.bbi.2013.07.007

Source DB:  PubMed          Journal:  Brain Behav Immun        ISSN: 0889-1591            Impact factor:   7.217


  83 in total

Review 1.  α-Synuclein pathology in Parkinson's disease and related α-synucleinopathies.

Authors:  Michael X Henderson; John Q Trojanowski; Virginia M-Y Lee
Journal:  Neurosci Lett       Date:  2019-06-03       Impact factor: 3.046

Review 2.  Cognitive decline in Parkinson disease.

Authors:  Dag Aarsland; Byron Creese; Marios Politis; K Ray Chaudhuri; Dominic H Ffytche; Daniel Weintraub; Clive Ballard
Journal:  Nat Rev Neurol       Date:  2017-03-03       Impact factor: 42.937

Review 3.  Role of MCP-1 and CCR2 in alcohol neurotoxicity.

Authors:  Kai Zhang; Jia Luo
Journal:  Pharmacol Res       Date:  2018-11-22       Impact factor: 7.658

4.  Depression Comorbid With Stroke, Traumatic Brain Injury, Parkinson's Disease, and Multiple Sclerosis: Diagnosis and Treatment.

Authors:  Susan K Conroy; Katherine B Brownlowe; Thomas W McAllister
Journal:  Focus (Am Psychiatr Publ)       Date:  2020-04-23

5.  Peripheral administration of the selective inhibitor of soluble tumor necrosis factor (TNF) XPro®1595 attenuates nigral cell loss and glial activation in 6-OHDA hemiparkinsonian rats.

Authors:  Christopher J Barnum; Xi Chen; Jaegwon Chung; Jianjun Chang; Martha Williams; Nelly Grigoryan; Raymond J Tesi; Malú G Tansey
Journal:  J Parkinsons Dis       Date:  2014       Impact factor: 5.568

Review 6.  Microglial phenotypes in Parkinson's disease and animal models of the disease.

Authors:  Valerie Joers; Malú G Tansey; Giovanna Mulas; Anna R Carta
Journal:  Prog Neurobiol       Date:  2016-04-20       Impact factor: 11.685

Review 7.  The implication of neuronimmunoendocrine (NIE) modulatory network in the pathophysiologic process of Parkinson's disease.

Authors:  Yan Shen; Xingfang Guo; Chao Han; Fang Wan; Kai Ma; Shiyi Guo; Luxi Wang; Yun Xia; Ling Liu; Zhicheng Lin; Jinsha Huang; Nian Xiong; Tao Wang
Journal:  Cell Mol Life Sci       Date:  2017-06-16       Impact factor: 9.261

8.  Association of polymorphisms in the MCP-1 and CCR2 genes with the risk of Parkinson's disease.

Authors:  Yan Wang; Minhua Zhou; Yong Wang; Deqi Jiang; Xun Deng
Journal:  J Neural Transm (Vienna)       Date:  2019-08-30       Impact factor: 3.575

Review 9.  Combination therapies: The next logical Step for the treatment of synucleinopathies?

Authors:  Elvira Valera; Eliezer Masliah
Journal:  Mov Disord       Date:  2015-09-21       Impact factor: 10.338

10.  Cognitive impairment in rheumatoid arthritis: role of lymphocyte subsets, cytokines and neurotrophic factors.

Authors:  Laura E Petersen; Talita S A Baptista; Júlia K Molina; Julia G Motta; Aline do Prado; Deise M Piovesan; Tatiana de Nardi; Thiago W Viola; Érica L M Vieira; Antonio L Teixeira; Rodrigo Grassi-Oliveira; Moisés Evandro Bauer
Journal:  Clin Rheumatol       Date:  2018-01-25       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.